The first ECLS perfusion device manufactured in Russia

We have developed a device that makes life-saving technology using artificial circulation available.

Application of ECLS perfusion device in organ transplantation

"Diagnostic" ECLS to assess the viability of donor organs before transplantation - an innovative discovery in transplantology

Application of ECLS based on ECMO in emergency system

We have developed a device that makes life-saving technology using artificial circulation available.

Learn more

ABOUT THE COMPANY

We have developed a device that makes life-saving technology using artificial circulation available.

The technology is founded on an emergency circulatory restoration technique.

Learn more

Association of Engineers, Doctors and
Entrepreneurs

Production in Russia

Unique technology

OUR TEAM
Oleg Reznik
Author of the technology, Professor, DMedSc
Andrey Skvortsov
Development Director, cardiac surgeon, CMD, PhD
Elena Averina
Director of Transbiotech
Igor Filatov
Head of development and production
OUR TEAM
Oleg Reznik
Author of the technology, Professor, DMedSc
Andrey Skvortsov
Development Director, cardiac surgeon, CMD, PhD
Elena Averina
Director of Transbiotech
Igor Filatov
Head of development and production
Oleg Reznik
Author of the technology, Professor, DMedSc
Andrey Skvortsov
Development Director, cardiac surgeon, CMD, PhD
Igor Filatov
Head of development and production
Elena Averina
Director of Transbiotech

ADVANTAGES

Our perfusion device outpaces the market in several characteristics at once:

5 KILOGRAMS

The maximum weight of the device with a set of consumables does not exceed 5 kilograms. This is 4 or more times lighter than the models of foreign manufacturers.

5 HOURS

The battery capacity allows to achieve at least 5 hours of continuous operation, which is 2 times longer, 2 times longer than the models of foreign manufacturers.

5 TECHNOLOGIES

5 technologies of ECLS application: in emergency medical services (EMS) and intensive care units, transplantation, cardiac surgery, high-risk endovascular interventions and oncology.

OUR PARTNERS

To learn more about the project, leave your contacts,
and we'll get back to you!

To learn more about the project, leave your contacts,
and we'll get back to you!